Journal of Vaccines & Vaccination

Journal of Vaccines & Vaccination
Open Access

ISSN: 2157-7560

+1-947-333-4405

Editor-in-Chief

TKS Mukkur

TKS Mukkur
Editor-in-Chief
Associate Professor, School of Biomedical Sciences
Curtin University of Technology, Australia

Biography

Dr. TKS Mukkur is a Fellow of the Australian Society of Microbiology. He conducted research at institutions noted worldwide including Stanford University School of Medicine, Harvard University Medical School and Washington University in St Louis, Missouri, St Louis, USA and he have a total of 105 publications and supervised the research of 30 students [postgraduate + BSc (Hons)] and have held academic and/or research positions in Canadian and Australian organisations including CSIRO and universities. His major research interests are i)Identification of immunomodulatory and bacterial biofilm dispersing agents from traditional medicinal plants of different ethno-botanical origins and to ii)Apply modern life sciences technologies for development of diagnostic assays, discovery of novel antimicrobials and affordable non−invasive vaccines for infectious diseases of humans and animals, using live attenuated bacterial pathogens as vaccines and deliver vectors for heterologous antigens including tumour-associated and tumour-specific antigens.

Research Interest

His major research interests are i)Identification of immunomodulatory and bacterial biofilm dispersing agents from traditional medicinal plants of different ethno-botanical origins and to ii)Apply modern life sciences technologies for development of diagnostic assays, discovery of novel antimicrobials and affordable non−invasive vaccines for infectious diseases of humans and animals, using live attenuated bacterial pathogens as vaccines and deliver vectors for heterologous antigens including tumour-associated and tumour-specific antigens.

Toshi Nagata

Toshi Nagata
Editor-in-Chief
Professor, Department of Health Science
Hamamatsu University School of Medicine, Japan

Biography

Toshi Nagata is a professor of Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu, Japan. He has received a PhD in molecular biology in Osaka University, Osaka, Japan in 1989. He had his postdoctoral training during 19891992 at National Institute of Child Health and Human Development NICHD, National Institutes of Health NIH, Bethesda, USA. Then, he was an assistant professor at Department of Parasitology, Yokohama City University, Yokohama, Japan during 1995-1997. Then, he was an associate professor at Department of Microbiology and Immunology, Hamamatsu University School of Medicine, Hamamatsu, Japan during 1997-2006. Since then, he has been a professor of Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu, Japan. He is serving as a reviewer of many reputed journals on immunology and microbiology, etc.

Research Interest

T-cell responses against intracellular pathogens DNA vaccination Antigen presentation Genetics of MHC molecules

Franco M. Venanzi

Franco M. Venanzi
Editor-in-Chief
Senior Researcher Professor of Physiology, Group Leader Unit of Translational Biology
University of Camerino, Italy

Biography

Franco Maria Venanzi, PhD, is a research professor of Physiology at the University of Camerino (UNICAM) Italy, where is Head of the Laboratory of Translational Biology Laboratory. His research is in the area of cancer vaccines and cancer immunotherapy. Since the mid-90s his research is aimed at developing DNA-based vaccines to treat cancer (e.g. breast cancer and melanoma). He pioneered the development of DNA vaccines against the oncogene HER-2/neu, and his preclinical studies contributed to the progression of the vaccine to the clinical setting. Since the work began he has sought to develop new approaches to further increase the potency of DNA vaccines using immune-stimulatory gene adjuvants. Recently, Prof. Venanzi scientific interest extended to the search of predictive biological markers to enable the selection of cancer patients who are most likely to benefit from dendritic cells-based immunotherapy. Prof. Venanzi serves as reviewer for various journal of oncology and immunology and as scientific consultant for small biotech companies.

Research Interest

DNA vaccines, Cancer Vaccines

Top